Storia in 10 fonti

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.

Raccontata da

independent.co.uk

www1.folha.uol.com.br

economictimes.indiatimes.com

morningstar.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

cnbc.comStai leggendo1 g fa

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Novo Nordisk hiked guidance to flat on Wegovy (5M+ prescriptions) but Eli Lilly's share gains and weak CagriSema results disappointed. Stock down 70% signals pipeline weakness and execution risk as obesity pioneer loses leadership to faster competitors.

originale

Timeline cronologica

lunedì 3 agosto 2026·independent.co.uk
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market
martedì 4 agosto 2026·www1.folha.uol.com.br
CEO da Novo Nordisk aposta em risco para retomar crescimento da fabricante do Ozempic
Mike Doustdar quer enfrentar a concorrência da Eli Lilly após cortes de empregos e pressão sobre preços

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Confronto fonti

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Timeline cronologica

GLP-1 battle heats up again as Novo claws its way back into race with Lilly

CEO da Novo Nordisk aposta em risco para retomar crescimento da fabricante do Ozempic

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks - Novo Nordisk

Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Donas do Mounjaro e do Ozempic aumentam previsão de lucro com boom de canetas emagrecedoras

Lilly climbs, Novo falls as obesity drug battle intensifies

Obesità, Novo Nordisk alza le previsioni, ma restano i dubbi sulla sostenibilità. La reazione del mercato |…

Novo vs. Lilly: Q2's cardiometabolic grudge match

Novo Nordisk shares slide after guidance disappoints investors

Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks - Novo Nordisk

Lilly climbs, Novo falls as obesity drug battle intensifies

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Obesità, Novo Nordisk alza le previsioni, ma restano i dubbi sulla sostenibilità. La reazione del mercato | MilanoFinanza News

Donas do Mounjaro e do Ozempic aumentam previsão de lucro com boom de canetas emagrecedoras

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?